Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback